On July 16, 2026 Trethera Corporation ("Trethera"), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, reported a comprehensive peer-reviewed manuscript describing deoxycytidine kinase (dCK) as a promising novel metabolic target that may enable a new class of precision cancer therapies. The article, published in Nucleosides, Nucleotides & Nucleic Acids, reviews decades of scientific study of the deoxyribonucleoside salvage pathway and highlights TRE-515 as the first dCK inhibitor to advance into human clinical testing.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The review describes how many tumors become increasingly dependent on the salvage pathway to maintain DNA precursor pools during rapid proliferation, DNA damage, and therapeutic stress. By selectively inhibiting the salvage pathway’s rate-limiting enzyme dCK, TRE-515 is designed to exploit a metabolic vulnerability that may exist across multiple tumor types while sparing normal tissues that primarily rely on de novo nucleotide synthesis.
The publication summarizes evidence demonstrating that specific genetic alterations—including BRCA2 deficiency and mutant p53—increase tumor reliance on dCK-mediated deoxyribonucleoside salvage. The authors further review emerging preclinical data supporting dCK inhibition in combination with DNA-damaging agents and radiation therapy that cause replication stress, suggesting that nucleotide salvage inhibition may enhance the activity of standard-of-care therapies across multiple tumor types.
"The data linking deoxyribonucleoside salvage to tumor growth and survival are very compelling but underappreciated relative to the historical focus on the de novo synthesis pathway," said Dr. Peter M. Clark, Professor of Molecular and Medical Pharmacology at the David Geffen School of Medicine at UCLA and publication first author. "This review highlights growing evidence that many tumors also depend on the deoxyribonucleoside salvage pathway under conditions of replication stress and DNA damage."
"True innovation doesn’t come from improving yesterday’s medicines—it comes from opening entirely new biological pathways for therapy," said Dr. Ken Schultz, Trethera Chief Executive Officer and publication co-author. "This publication reinforces the growing recognition that targeting dCK represents a new frontier in precision cancer medicine and positions TRE-515 at the forefront of that opportunity."
The publication also highlights the translational tools supporting TRE-515 development, including pharmacodynamic biomarkers designed to measure dCK activity and pathway inhibition to help guide future clinical studies.
Biochemical pathways for the supply of deoxyribonucleoside triphosphate pools. TRE-515 blocks the salvage pathway, which becomes upregulated during cancer growth and autoimmune disease.
(Press release, Trethera, JUL 16, 2026, View Source [SID1234669280])